Scholarlink

Purpose <p>Brain metastases (BMs) present a significant therapeutic challenge due to limited blood-brain barrier permeability, which restricts the efficacy of systemic treatments. To address this, we systematically evaluated the effectiveness and safety of encorafenib plus binimetinib in patients with BMs.</p> Methods <p>We conducted a systematic literature search from inception to January 2025 to assess the intracranial efficacy of encorafenib in combination with binimetinib. Studies reporting related outcomes were included.</p> Results <p>Four studies, encompassing 1,789 patients with 472 BMs, were included. The pooled intracranial overall response rate (ORR) was approximately 48% with substantial variability across studies. Additionally, about 29% of patients achieved stable disease (SD). Meta-regression suggested that sex, performance status, number of brain lesions, and prior treatments may influence treatment response.</p> Conclusion <p>Encorafenib plus binimetinib has demonstrated promising outcomes in the setting of BMs. Given the limitations of the available data, further prospective and controlled studies are required to validate our findings and identify the optimal patient population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The safety and efficacy of encorafenib plus binimetinib for brain metastases: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Amirmohammad Bahri,
  • Ali Dehghan Banadaki,
  • Mobina Bayani,
  • Ibrahim Mohammadzadeh,
  • Milad Shafizadeh,
  • Mohammad Amin Habibi,
  • Bardia Hajikarimloo

摘要

Purpose

Brain metastases (BMs) present a significant therapeutic challenge due to limited blood-brain barrier permeability, which restricts the efficacy of systemic treatments. To address this, we systematically evaluated the effectiveness and safety of encorafenib plus binimetinib in patients with BMs.

Methods

We conducted a systematic literature search from inception to January 2025 to assess the intracranial efficacy of encorafenib in combination with binimetinib. Studies reporting related outcomes were included.

Results

Four studies, encompassing 1,789 patients with 472 BMs, were included. The pooled intracranial overall response rate (ORR) was approximately 48% with substantial variability across studies. Additionally, about 29% of patients achieved stable disease (SD). Meta-regression suggested that sex, performance status, number of brain lesions, and prior treatments may influence treatment response.

Conclusion

Encorafenib plus binimetinib has demonstrated promising outcomes in the setting of BMs. Given the limitations of the available data, further prospective and controlled studies are required to validate our findings and identify the optimal patient population.